Back to discover
Disease
Thymus Neoplasms
Late-stage therapeutic developmentEmerging research
2
Publications
6
Clinical trials
2
Related conditions
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Genomic characterization of thymic epithelial tumors in a real-world dataset.
Research2023-09-12ESMO open
Research2023-09-09Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials expected to report results, the earliest in Q1 2029.
Upcoming Milestones
- Q1 2029Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Q4 2030Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical Trial
- Q2 2034Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20292026-05-12
Upcoming trial readoutImportant
Results expected Q2 20342026-06-17
Clinical MilestonesViewHide
Results expected
- 2026-06-17Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaResults expected Q2 2034
- 2026-06-16Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical TrialResults expected Q4 2030
- 2026-05-12Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.Results expected Q1 2029
Activity timeline3
- 2026-06-17ClinicalPhase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaResults expected Q2 2034
- 2026-06-16ClinicalAdjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical TrialResults expected Q4 2030
- 2026-05-12ClinicalEfficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.Results expected Q1 2029
Clinical trials
The current development programme across all trial phases.
Clinical programme
6
3
1
1
Recruiting
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes5
- Neoplasms, Glandular and Epithelial2
- Thymoma2
- Thymus Neoplasms2
- Lung Neoplasms1
- Neuroendocrine Tumors1
Leading journals2
- ESMO open1
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer1
Leading researchers8
- Ahmad U1
- Appel S1
- Asamura H1
- Bille A1
- Boubia S1
- Brambilla C1
- Cangir AK1
- Carbone DP1
Affiliations (unnormalised)6
- and Thoracic Institute at Cleveland Clinic1
- Ankara University Faculty of Medicine1
- Asan Medical Center1
- Azienda Ospedaliero-Universitaria Pisana1
- Baggiovara Civil Hospital1
- Chaim Sheba Medical Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Tumors or cancer of the THYMUS GLAND.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.